ODC1 and leishmaniasis: Examples include inhibitors of polyamine/ornithine decarboxylase (e.g., eflornithine in HAT), disruption of sterol/ergosterol biosynthesis, membrane‐active amphotericin formulations and alkylphosphocholine drugs used in leishmaniasis (e.g., miltefosine), and emerging scaffolds that perturb proteostasis or organellar function; cytology‐based MoA profiling in trypanosomatids likewise reveals non‐oxidative mechanisms [4,111].